RNA-based therapy combats melanoma in mouse models

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Investigators at the Icahn School of Medicine at Mount Sinai have designed a RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login